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ABSTRACT
Objective In this systematic review, we aimed to
summarise the empirical evidence on common mental
disorders (CMDs), cognitive impairment, frailty and health-
related quality of life (HRQoL) among people living with
HIV aged ≥50 years (PLWH50 +) residing in sub-Saharan
Africa (SSA). Specifically, we document the prevalence and
correlates of these outcomes.
Design, data sources and eligibility criteria The
following online databases were systematically searched:
PubMed, CINAHL, PsycINFO, Embase and Scopus up
to January 2021. English-language publications on
depression, anxiety, cognitive function, frailty and quality of
life among PLWH50 + residing in SSA were included.
Data extraction and synthesis We extracted information,
including study characteristics and main findings. These
were tabulated, and a narrative synthesis approach was
adopted, given the substantial heterogeneity among
included studies.
Results A total of 50 studies from fifteen SSA countries
met the inclusion criteria. About two-thirds of these studies
emanated from Ethiopia, Uganda and South Africa. Studies
regarding depression predominated (n=26), followed by
cognitive impairment (n=13). Overall, PLWH50 + exhibited
varying prevalence of depression (6%–59%), cognitive
impairments (4%–61%) and frailty (3%–15%). The correlates
of CMDs, cognitive impairment, frailty and HRQoL were rarely
investigated, but those reported were sociodemographic
variables, many of which were inconsistent.
Conclusions This review documented an increasing
number of published studies on HIV and ageing from
SSA. However, the current evidence on the mental
and well-being outcomes in PLWH50 + is inadequate
to characterise the public health dimension of these
impairments in SSA, because of heterogeneous findings,
few well-designed studies and substantial methodological
limitations in many of the available studies. Future work
should have sufficiently large samples of PLWH50+,
engage appropriate comparison groups, harmonise the
measurement of these outcomes using a standardised
methodology to generate more robust prevalence
estimates and confirm predictors.
PROSPERO registration number CRD42020145791.

BACKGROUND
All societies globally are experiencing an
ageing population—some are in its early
stages, and some are more advanced.1

Strengths and limitations of this study
►► This is the first comprehensive review of common

mental disorders, cognitive impairment, frailty and
quality of life among older adults living with HIV in
Saharan Africa, synthesising the current evsub-
idence regarding the prevalence and correlates of
these outcomes.
►► Our expanded search of five online databases and
snowballing techniques minimised the risk of missing relevant studies.
►► Meta-analysis was not conducted due to extensive
heterogeneity across the studies in methods and
presentation of results.
►► We observed substantial methodological limitations
in many of the included studies, for example, small
sample sizes, making it difficult to characterise the
real public health dimension of these impairments
in the region.

Likewise, the proportion of people living with
HIV (PLWH) aged ≥50 years (considered
as older adults within the HIV literature) is
growing rapidly across the globe,2 demanding
an increase in research, policy and practice to
address the complex needs of this vulnerable
group.3 In 2016, there were around 6 million
PLWH50 + globally, representing 16% of the
entire adult HIV population.2 This proportion was projected to reach 21% by the end
of 2020, with Southern and Eastern Africa
containing the vast majority of PLWH50+.2
The increase in older PLWH is mainly driven
by two factors: effective antiretroviral therapy
(ART) and new HIV infections among the
elderly.4
This rapidly growing segment of
PLWH50 + yields new challenges. Several
HIV and ageing cohorts (mostly from high-
income countries, HICs) are pointing out an
elevated burden of physical conditions (eg,
cardiometabolic diseases), mental morbidities (eg, depression, cognitive disorders),
psychosocial challenges (eg, stigma, loneliness) and geriatric syndromes (eg, frailty)
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among PLWH ≥50 years (PLWH50+) compared with
their uninfected counterparts.4–6 Unfortunately, the
mechanisms for the heightened risk of poor outcomes
among PLWH50 + are not fully understood but span a
host of disease-related factors, legacy of the early years of
the HIV epidemic and host vulnerability factors.4 Frailty,
common mental disorders (CMDs) such as depression
and anxiety, and cognitive impairments are of particular
concern in this population.4–6 Frailty is an important
emerging indicator of vulnerability that is increasingly
being evaluated among individuals ageing with HIV.7 It
describes a state of physiological vulnerability that, in the
presence of internal or external stressors, puts a person
at an elevated risk of adverse clinical outcomes, such
as hospitalisation, functional disability and mortality.8 9
Overall, mental morbidities and frailty are understudied
in the literature despite their elevated burden and potential adverse impacts on HIV treatment and health-related
quality of life (HRQoL).
Despite the apparent need to sharpen the focus on
the needs of the growing cohort of PLWH50+, this population is being neglected in HIV care and prevention
efforts, especially in low-
income and middle-
income
settings of sub-Saharan Africa (SSA). In SSA, this concern
is not just based on the close association between ageing
and physical, cognitive, mental impairments, but also on
the recognition that older adults are not considered to
be a priority for policy issues. They are marginalised and
increasingly vulnerable to greater poverty.10 11 Thus, the
burden and determinants of physical and mental impairments in these adults in SSA, the region most affected by
HIV globally, are largely undocumented.12
The course and implication of physical and mental
morbidities among PLWH50 + are well described in HICs,
but it is an emergent research area in SSA. However, since
2010, the SSA region has witnessed a rise in interest in
HIV and ageing outcomes, evidenced by the establishment of cohort studies of older people in different parts
of Africa.13–15 This is encouraging since data from HICs
may not be readily generalised to SSA where differences in, for example, genetics, social environmental
milieu, formal and informal support systems will almost
certainly alter the risk profile and morbidity characteristics among PLWH50+. Therefore, the current review
aims to summarise the existing empirical evidence on
CMDs, cognitive impairment, frailty and HRQoL among
PLWH50 + in SSA by addressing the following specific
objectives.
1. Establish the prevalence of CMDs, cognitive impairment and frailty among PLWH50 + in SSA.
2. Identify the correlates of CMDs, cognitive impairment,
frailty and HRQoL among PLWH50 + in SSA.
METHODS
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to report the
study.16
2

Search strategy
Five online databases (PubMed, CINAHL, PsycINFO,
Embase and Scopus) were searched for publications.
The last search was conducted on 4 January 2021. The
following search terms were used: (HIV OR HIV-1 OR
HIV/AIDS OR HIV infections) AND (adult OR older
adult OR older people OR older individual OR elderly)
AND (Africa OR sub-Saharan Africa OR Africa South of
the Sahara) AND (cognitive impairment OR neurocognitive impairment OR neurological complication OR HIV-
associated neurocognitive disorder OR common mental
disorder OR depression OR depressive symptoms OR
depressive disorder OR anxiety OR anxiety disorder OR
quality of life OR health-related quality of life OR grip
strength OR hand strength OR frailty). We also searched
through the reference lists of included articles to access
additional articles. Details of the full search strategy are
provided in online supplemental file 1.
Studies were considered eligible if they: (1) involved
PLWH50 + or had participants whose mean/median age
was ≥50 years or aggregated their outcomes of interest by
age (including the ≥50 age category); (2) were conducted
within SSA; (3) were empirical and published in a peer-
reviewed journal and (4) reported any of our outcomes of
interest (CMDs, cognitive impairment, frailty or HRQoL).
We excluded studies that did not aggregate the outcomes
of interest by HIV status. We also excluded studies that
English languages. Two of the
were published in non-
authors (PNM and AM) independently screened the
titles, abstracts and full articles for eligibility and reached
consensus.
Data extraction and quality assessment
The two authors (PNM and AM) independently extracted
the following study characteristics using a similarly
designed extraction sheet: (1) first author; (2) country
and the year of publication; (3) sample description; (4)
how the outcome of interest was measured; (5) results
reported; (6) key findings on the outcome of interest.
For studies exclusively carried out among PLWH50+, we
computed or extracted the reported percentages of the
relevant outcomes. Similarly, for studies with middle-aged
participants but whose mean/median age was ≥50 years,
we also computed or extracted the reported percentages
for the relevant outcomes for the whole sample. For the
studies with middle-aged participants (but whose mean/
median age was not at least 50 years), we computed
percentages for participants who fell within the ≥50 category, which was usually provided in the papers. In some
studies, it was impossible to calculate these percentages.
Hence, the occurrence of a specific outcome was reported
in the original effect measure, for example, OR, median
or mean. Any disagreement between the reviewers during
data abstraction was also resolved by consensus.
We evaluated the quality of included studies using the
modified version of the Newcastle-Ottawa Scale.17 The
scale uses five parameters (sample size, sample representativeness, comparability between respondents and
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810
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non-
respondents, ascertainment of the outcome of
interest, and quality of descriptive statistics reporting)
to obtain a total score ranging from 0 to 5. A score ≥3
is considered a low risk of bias, while a score of <3 is
regarded as a high risk of bias.
Data synthesis and analysis
A narrative synthesis approach was used to compare
studies and describe the state of evidence on all reported
outcomes; by describing the effect estimates, for instance,
proportions, means with SD, and median with their IQRs.
Where applicable, ranges were used to summarise the
outcomes of interest reported. A meta-analysis could not
be done due to a limited number of studies and substantial heterogeneity among studies.
Patient and public involvement statement
The accompanying manuscript is part of broader doctoral
research work for the first author. During the conceptual
phase of this work, community engagement through
meetings with different stakeholders was carried out to
contextualise the issues of ageing and HIV at the coast of
Kenya (eg, in terms of priorities and preferences). These
stakeholders included the Kilifi and Mombasa counties' departments of Health, subcounty health management teams, and hospital management teams of various
health facilities at the study setting. The research team
received and incorporated useful feedback from these
meetings towards the design and implementation of
the project. It also led to further elaborations regarding
ongoing community engagement during and after the
study, including disseminating any work arising from this
project using these forums and others such as publications, hospital departmental meetings, patient groups and
conferences as an essential way to discuss the implications
of the findings. For this systematic review, patients were
not involved in the conduct of the study. However, the
results will be disseminated to the relevant patient groups
within the HIV clinics through feedback meetings.

RESULTS
Characteristics of included studies
We identified 8741 articles from the 5 online databases
and an additional 7 citations from snowballing. Of these,
2693 were duplicates. Hence, we screened 6055 titles and
abstracts for initial eligibility, out of which 575 articles
were identified. Full articles were obtained for these citations, of which 50 met the eligibility criteria (figure 1). The
eligible studies were conducted between 2006 and 2021
among 15 SSA countries of Uganda (n=13), South Africa
(n=12), Ethiopia (n=8), Tanzania (n=5), Nigeria (n=3),
Cameroon (n=2), Côte d’Ivoire (n=2), Senegal (n=2),
Kenya (n=2), Botswana (n=1), Zambia (n=1), Malawi
(n=1), Namibia (n=1), Togo (n=1) and Burkina Faso
(n=1). However, some of these studies were conducted in
multiple countries. Figure 2 shows the geographical distribution of these studies across the SSA region. Virtually
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810

Figure 1 Identification of eligible studies. PLWH, people
living with HIV; SSA, sub-Saharan Africa.

all the included studies were cross-sectional, except one
that presented data from a randomised trial.18 Eighteen
studies (36%) analysed baseline or follow-
up data of
different cohort studies.
About two-
thirds of the included studies (n=35)
recruited their HIV infected samples from clinical
settings.18–52 The rest obtained their samples from the
general population through household surveys and
community samples. Additionally, many of the studies
included samples of PLWH50 + lower than 100 (n=22).
Overall, the samples of PLWH50 + per study ranged from
19 to 1048,36 53 while those for HIV uninfected older
adults ranged from 17 to 4022.22 54

Figure 2 Geographical distribution of the included studies
within SSA. SSA, sub-Saharan Africa.
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Common HIV disease markers such as the duration of
HIV infection, current/nadir CD4 +T cell count, duration of ART use, viral suppression level among PLWH50 +
were reported in a few studies. However, there was extensive heterogeneity in how the information was reported
and the level of detail given. In 42% of the included
studies, all PLWH50 + were on ART. Six other studies
included only ART naïve PLWH50+. Among ART users,
viral suppression was reported in five studies where it was
documented to range from 73% to 90%. Nadir CD4 +T
cell count among PLWH50 + was reported in four studies
where most of the participants (about 60%) had a count
lower than 200. The duration of HIV infection among
PLWH50 + ranged from 3.5 to 12 years (among the few
studies that reported this variable).
Only eight studies examined the health outcomes
of interest using an exclusively HIV infected older
sample.25 33 40 45–49 Eighteen other studies used HIV uninfected older adults as comparison groups, while the rest
included HIV infected young adults (the ages varied
extensively).
Depression and anxiety
Depression was reported in 25 studies, while anxiety was
reported in two studies. Notably, depression was assessed
using multiple scales with diverse scoring systems. Six
of the studies used the 9-item Patient Health Questionnaire (PHQ-9), while a similar number used the Centre
for Epidemiological Studies Depression scale. Five
other studies used the Mini International Neuropsychiatric Interview (MINI), while the rest utilised a host of
different scales. On the other hand, anxiety was assessed
using the Schedule for Clinical Assessment in Psychiatry
and from clinical records.30 39 Nine of the depression
studies19 29 44 49 51 55–58 reported major depressive disorders
(MDD), while the remaining sixteen studies reported
the prevalence of depressive symptoms. To synthesise
and report the available evidence, depression (whenever used in this review) captures both the depressive
symptoms (derived from brief screening measures) and
Major Depressive Disorder (based on structured diagnostic interviews, for example, the MINI by specialised
professionals or trained non-specialised workers). More
information on this outcome is presented in the online
supplemental table 1.
Prevalence of depression and anxiety
Overall, the prevalence of depression ranged from 6%
to 59%. We found no clear pattern of over-
reporting
or under-
reporting of depression prevalence in the
included studies, considering the different cut-offs used.
For instance, in studies using the PHQ-9, the prevalence
of depression ranged from 47% to 49% (with a cut-off
of ≥5) and 16% to 45% when using a cut-off of ≥10. We
also noted a similar observation when we took the ART
status of PLWH into account. Specifically, the prevalence
of depression ranged from 8% to 59% among studies
whose participants were entirely on ART compared with
4

6% to 54% among studies with mixed or naïve PLWH.
However, studies that used structured interviews such as
the MINI, Composite International Diagnostic Interview
(CIDI) and Diagnostic and Statistical Manual of Mental
Disorders, fourth edition (DSM-IV) to assess for depression were noted to frequently report lower prevalence
of depression among PLWH50+ (ranging from 6% to
30%)44 57 compared with studies that used brief screening
scales such as the PHQ-9 (prevalence ranging from 8% to
59%).27 59
Of note, eight studies documented higher prevalence
of depression among PLWH50 + than their comparison
groups.20 23 27 36 37 43 55 56 On the contrary, 11 studies reported
a lower prevalence of depression among PLWH50 +
than their comparison groups.19 24 28 29 31 32 44 50 51 58 59 In
comparison, three other studies reported minimal or no
differences in depression between PLWH50 + and their
comparison groups.34 42 57 In one population-based study
conducted in rural South Africa, neither diagnosis nor
treatment of HIV was significantly associated with depression when compared with being uninfected.54
Anxiety was reported in two studies.30 39 In one of them,39
PLWH50 + on ART presented with the same proportion
of anxiety symptoms with HIV uninfected older adults at
3%. In the other study,30 the prevalence of anxiety disorders among PLWH50 + on ART was 21% compared with
22% in HIV infected young adults (18–50 years).
Reported correlates of depression
Correlates of depression among PLWH50 + were reported
only in eight studies.27 28 46 48 51 54 55 58 Among sociodemographic variables, older age,27 54 declining socioeconomic
status,55 being unemployed,46 being female,28 58 HIV
status disclosure48 and urban residency58 were associated
with an elevated risk of depression while being married,
employed (full-
time or part-
time work),54 old age,51
higher educational attainment48 and belonging to the
highest wealth quintile28 were associated with reduced
levels of depression. However, in some studies, household wealth quintile, education levels,51 and age25 were
not significant correlates of depression. In other studies,
being a current/former smoker,46 increasing disability
scores, decreasing mean handgrip strength, reported
back pain, not having hypertension,55 HIV stigma48 and
caregiving (for adult children)58 were significantly associated with elevated levels of depression. On the other
hand, receiving a government grant58 and resilience48
were significantly associated with reduced levels of
depression. Details of this data are presented in online
supplemental table 1.
Cognitive and neurological functioning
These outcomes were reported by 13 studies, as highlighted in table 1. Of these, five studies quantified the
prevalence of HIV-
associated neurocognitive disorders (HAND) using different measures,25 35 38 40 49 two
studies reported findings on dementia21 60 while five
studies documented findings on cognitive function/
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810
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Sample size

Treatment status Assessment tool
of PLWH
used

253 PLWH50+

102 PLWH50+

Cross-sectional

Cross-sectional

Eaton, (2020);
Tanzania25

Oumar, (2020);
Burkina Faso40

235 PLWH50+

Cross-sectional

Kellett-Wright,
(2020); Tanzania49

All on ART

94.8% on ART

95.5% on ART

Mini Mental State
Examination
(MMSE)

Comprehensive
NP battery

International HIV
Dementia Scale
(IHDS) and (Six
Item Dementia
Screen, IDEA)

Diagnostic
accuracy (area
under the
receiver operating
characteristic
curve: 0.64–0.67
for IHDS and 0.65–
0.71 for IDEA

Frascati criteria for NR
classifying HAND

Frascati criteria for NR
classifying HAND

Frascati criteria
with a detailed
consensus panel
discussion

Studies reporting the prevalence of HIV-associated neurocognitive disorders (HAND) or cognitive impairment

Study design

Information
Cut-off score or on local tool
diagnosis criteria validation

Summary of prevalence estimates and correlates for cognitive impairment/neurological impairment

Author,
publication year
and country

Table 1

23.5% had
neurocognitive
disorders

Prevalence of
symptomatic
HAND (HAD and
MND) was 21.7%.

Prevalence of
symptomatic
HAND (MND and
HAD) was 25.3%.

Prevalence
estimates/
other results for
PLWH50+

Continued

In a multivariate
analysis, age
(OR 4.6) and
educational status
(OR 2.6) were
associated with
neurocognitive
disorders.

PLWH were
at higher risk
of having
symptomatic
HAND if they
lived alone(OR
2.6), were illiterate
(OR 3.2) or older
at the time of
HIV diagnosis
(OR 1.1). HIV-
specific factors
were not related
to symptomatic
HAND. Vascular
risk factors,
such as smoking
status, were not
associated with
symptomatic
HAND.

NR

Correlates
reported
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411 PLWH50+

Studies reporting NP test scores

Cross-sectional

Ssonko, (2018);
Uganda33

67PLWH56+;
526 PLWH (18–55
years)
1048 PLWH40+;
4011 HIV
uninfected older
adults ≥40 years

Cross-sectional

Tsegaw, (2017);
Ethiopia35

64 PLWH50+;
281 PLWH (20–49
years)

Sample size

Kobayashi, (2019); Population survey
South Africa53

Cross-sectional

Mugendi, (2019);
Kenya38

Study design

Continued

Author,
publication year
and country

Table 1

All on ART

63.9% on ART

All on ART

All on ART

Folstein’s MMSE

Brief cognitive
battery
(orientation,
immediate and
delayed recall).

IHDS

NR

≤1.5 SDs below
the mean
composite time
orientation and
memory score.

≤9.5

NR

Locally adapted

NR

Montreal Cognitive Combined scores NR
Assessment
of the two tools:
(MoCA) and IHDS a score of ≤26 on
MoCA and ≤10 on
the IHDS.

Treatment status Assessment tool
of PLWH
used

Information
Cut-off score or on local tool
diagnosis criteria validation

Correlates
reported

Continued

Independent
predictors of lower
cognitive score
were being older,
female, unmarried,
not working,
having low formal
education, low
socioeconomic
status, and
having a history
of cardiovascular
conditions.

Reported
correlates not
aggregated by
age.

Mild cognitive
NR
impairment was
associated with
falls in the previous
12 months.

4.0% of PLWH40 +
had cognitive
impairment
compared with
9.0% of uninfected
older adults ≥40
years

61.2% among
PLWH56 + had
HAND

Among PLWH50+, Reported
symptomatic
correlates not
HAND was 19.2% aggregated by
age.

Prevalence
estimates/
other results for
PLWH50+
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Cross-sectional

Moucheraud,
(2020); Malawi51

Studies reporting dementia

Cassimjee, (2017); Cross-sectional
South Africa22

Population survey

Asiimwe, (2020);
South Africa61

Study design

Continued

Author,
publication year
and country

Table 1

68.6% on ART

33 PLWH50+;
NR
17 HIV uninfected
older adults (mean
age 52.2)

NR

NR

NR

Summarised
Previously
mean cognitive
validated in the
scores between
study setting
participants with
and without HIV on
the two measures.

Dementia Rating
N/A
Scale-2, the
Stroop Colour and
Word Test, the
Symbol Digits Test
and the D-KEFS
Trail Making Test.

Brief cognitive
battery (MMSE)

A battery of
conventional
instruments and
the Oxford
Cognitive Screen-
Plus (OCS-Plus)

Treatment status Assessment tool
of PLWH
used

74 PLWH50 + and All on ART
60 young PLWH
(30–49) years

1048 PLWH40+;
3512 HIV
uninfected older
adults ≥40 years

Sample size

Information
Cut-off score or on local tool
diagnosis criteria validation

NR
PLWH, in
comparison to
the uninfected
group, had
significantly poorer
performance
profiles in
global cognitive
functioning,
memory, executive
functioning,
psychomotor
functioning, and
processing speed.

Continued

ART use was
non-significantly
associated with
better cognitive
outcomes among
PLWH in both
instruments.

Correlates
reported

Mean cognitive
NR
scores:
16.0 among
PLWH50 + vs 17.4
among young
PLWH.

PLWH scored on
average 0.06 (95%
CI 0.01 to 0.12)
SD units higher on
the conventional
cognitive function
measure and 0.02
(95% CI −0.07
to 0.04) SD units
lower on the OCS-
Plus measure
than HIV-negative
participants.

Prevalence
estimates/
other results for
PLWH50+
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Cross-sectional

Population survey

400 HIV infected
adults (20–53
years old)

55 PLWH50+;
1095 HIV
uninfected older
adults ≥50 years

Sample size

Cross-sectional

62 PLWH60+;
All on ART
162 HIV uninfected
older adults ≥60
years

All on ART

86.1% on ART

Extracted from
participants
medical notes

IHDS

Brief Community
Screening
Instrument for
Dementia

Treatment status Assessment tool
of PLWH
used

Clinical notes

≤10 on IHDS

NR

NR

Not validated

Previously
validated

Information
Cut-off score or on local tool
diagnosis criteria validation

19.0% in
PLWH60 +
had peripheral
neuropathy

The odds of
having a positive
dementia screen
increased
progressively
with increasing
participants' age,

18.2% of
PLWH50 +
had dementia
compared with
10.7% of the
uninfected older
adults ≥50 years

Prevalence
estimates/
other results for
PLWH50+

NR

Not aggregated
by age

Dementia status
was associated
with HIV infection
(OR 2.2, 95% CI
1 to 4.5), older
age (OR 1.0, 95%
CI 1.0 to 1.1)
and depressive
symptoms (OR
2.7, 95% CI 1.8 to
3.9).

Correlates
reported

ART, antiretroviral treatment; D-KEFS, Delis-Kaplan executive function system; HAD, HIV-associated dementia; MND, mild neurocognitive disorder; NA, not applicable; NP,
neuropsychological; NR, not reported; PLWH50+, people living with HIV ≥50 years old.

Obimakinde,
(2020); Nigeria39

Studies reporting HIV-associated neuropathy

Atashili, (2013);
Cameroon21

Joska, (2019);
South Africa60

Study design

Continued

Author,
publication year
and country

Table 1
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impairment.22 33 51 53 61 The remaining study reported
the proportion of HIV-associated peripheral neuropathy
among PLWH50+.39
Prevalence estimates of reported outcomes
The prevalence of symptomatic HAND among PLWH50 +
on ART ranged from 19%38 to 61%.35 Two of the HAND
studies documented elevated proportions of symptomatic
HAND among PLWH50 + on ART compared with their
younger counterparts.35 38 In rural South Africa, Joska et al
examined the prevalence of dementia and its associations
in a population survey of 1150 rural elderly participants.
They found no significant differences in the prevalence
of dementia between PLWH50+ (86% on ART) and HIV
uninfected counterparts 18% vs 11%, respectively.60 In a
different study in rural South Africa, a baseline analysis of
the Health and Ageing in Africa—A Longitudinal Study
of an INDEPTH Community (HAALSI), HIV infected
older adults (64% on ART) registered a lower prevalence
of cognitive impairment (4%) than their uninfected
peers (9%).53 In a separate analysis of the same baseline
data of the HAALSI cohort,61 HIV infected older adults
scored on average 0.06 (95% CI 0.01 to 0.12) SD units
higher on a conventional cognitive function measure and
0.02 (95% CI − 0.07 to 0.04) SD units lower when using
the Oxford Cognitive Screen-Plus (OCS-Plus) measure
than their HIV-negative counterparts.
Correlates of cognitive function/impairment
The correlates of cognitive function/impairment were
reported in seven studies. The key predictors of reduced
cognitive function were mainly sociodemographic: older
age (≥50 years),21 40 53 60 living alone,25 being illiterate or
having low formal education level,25 53 being older at the
time of HIV diagnosis,25 being female, unmarried and
having low socioeconomic status53 were associated with
a higher risk of impairment. However, in some studies,
the effects of age, education and marital status were not
significant.25 60 Other correlates of cognitive impairment
included the presence of depressive symptoms,60 a history
of cardiovascular conditions53 and a history of falls in the
past 12 months.33 HIV specific factors (such as nadir CD4
count, ART use)25 61 and vascular risk factors (such as
smoking status, body mass index and blood pressure)25
were not associated with cognitive impairment.
Frailty/grip strength
Prevalence estimates
Frailty was reported in three studies.33 47 62 In the first study,
a hospital-based cross-sectional study of 145 PLWH50 +
on ART in Tanzania, frailty assessment was completed
using three measures (the Fried frailty phenotype
(FFP), the Clinical Frailty Scale (CFS) and Brief Frailty
Instrument for Tanzania (B-FIT 2)).47 In this study, the
authors reported low levels of frailty: 3% (when using the
FFP method) and 1% (when using the CFS and BFIT-2
methods). The second study documented a similar prevalence of frailty among 292 PLWH50+ (ART status not
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810

reported) and 322 HIV uninfected peers in rural South
Africa (15% vs 18%, respectively), using a modified
version of the FFP.62 In the third study, increasing frailty
scores were significantly associated with increasing polypharmacy levels in a sample of 411 PLWH50 + on ART
in Uganda.33 Five other studies18 45 57 63 64 reported mean
handgrip strength as an indicator of frailty, as shown in
table 2.
Reported correlates of frailty
The correlates of frailty were reported in two studies.
Being female, unmarried47 and older47 62 were significantly associated with worse frailty scores, and there
were no associations between inflammatory biomarkers
with frailty.62 Factors associated with mean handgrip
strength were reported in four of the studies. In one, HIV
status was significantly associated with weaker handgrip
strength.57 In another study, being female and divorced/
widowed were significantly associated with weaker handgrip strength, while having a secondary education level
was significantly associated with better handgrip strength.
Table 2 gives details of this outcome.
Health-related quality of life
This outcome was reported in eight studies. Three-quarters
of the studies used the WHO Quality of Life measure to
assess HRQOL. The overall mean quality of life scores
(out of 100) ranged from 42 to 83 among PLWH50 +
on ART. In two studies, PLWH50+ (partially on ART)
reported better quality of life scores than their uninfected
counterparts.63 65 In contrast, four other studies reported
a lower quality of life scores39 41 52 66 among PLWH50 +
compared with to HIV uninfected older adults or HIV
infected young adults.
The correlates of quality of life were reported in only
one study,65 where having some source of income and
being in the upper two wealth quintiles were significantly
associated with better quality of life among PLWH50+.
Additionally, being female and previously married were
associated with reduced odds of good quality of life in
PLWH50+. Table 3 gives more details on this outcome.
Overall, a significant number of the included studies
(about 35%) had a low quality score (≤2 – indicating a
high risk of bias).19–22 26 29 31 35–41 48 51 66 Specifically, about
two-thirds of the included studies did not report participant response rates. Sixteen studies used non-probability
sampling methods or did not report their sampling
methods. Close to half of the included studies had
substantially small samples of PLWH50+ (≤100). Furthermore, a substantial number of studies (about 40%)
provided scarce information regarding their measures’
reliability and validity. Details of the quality assessment of
all included studies are captured in online supplemental
table 2.
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Sample size

411 PLWH50+

292 PLWH50 +
and 322 HIV
uninfected adults
(≥50) years.

145 PLWH50+

Bernard, (2020);
Coˆte d’Ivoire &
Senegal45

Cross-sectional

333 PLWH50+

Studies that assessed handgrip strength

Cross-sectional

Cross-sectional

Edwards, (2020);
South Africa62

Ssonko, (2018);
Uganda33

Cross-sectional

Bristow, (2021);
Tanzania47

Studies that assessed frailty comprehensively

Study design

All on ART

All on ART

NR

99.3% on ART

Presence of ≥3
of the 5 FFP
phenotypes

FFP: A score of
1–2 was prefrail,
and a score of ≥3
was frail; B-FIT
(A score of 8/20);
CFS (a score of
5–9)

Cut-off score

Calibrated Jamar
hydraulic hand
dynamometer

NR

Adapted in the
local population

B-FIT and FFP
previously
validated in
Tanzania.

Tool validation

A performance
NR
less to the median
obtained in each
gender group
(male/female)

Self-report 40
NR
-item Frailty Index
Questionnaire

FFP

Fried frailty
phenotype (FFP),
Clinical Frailty
Scale (CFS) and
B-FIT 2.

Treatment status Assessment tool
of PLWH
used

Summary of prevalence estimates and correlates for frailty and handgrip strength

Author,
publication year
and country

Table 2

Continued

Increasing
Frailty score was
associated with
increasing levels of
polypharmacy.

The prevalence of
frailty increased
with age. There
was no association
between any of
the inflammatory
biomarkers
and frailty and
prefrailty.

FFP frailty was
associated with
female gender
(p=0.006), marital
status (p=0.007)
and age (p=0.038).
Weight loss was
the most common
FFP domain
failure.

Correlates
reported

43.2% of women NR
had low grip
strength. 42.5% of
men had low grip
strength.

Frailty Index
Scores of 5 to 6
(PR 10.6, 95% CI
1.4 to 78, p=0.02),
and seven or more
(PR 17.4, 95%
CI 2.4 to 126.5,
p=0.005) were
associated with
polypharmacy.

Frailty was similar
for HIV negative
and PWH (17.7%
vs 14.7%, p=0.72)
respectively as
was prefrailty
status (66.5% vs
63.4%).

2.8% (95% CI
0.09% to 5.4%)
when using the
FFP.
0.68% (95% CI
−0.66% to 2.04%)
when using the
CFS or B-FIT 2).

Prevalence
estimates/
other results for
PLWH50+
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142 PLWH50+;
2722 HIV
uninfected older
adults ≥50 years

189 PLWH50+;
2017 HIV affected
50+; and 104 HIV
uninfected older
adults ≥50 years

Cross-sectional

Cross-sectional

Negin, (2012);
South Africa57

Scholten, (2011);
Uganda64

Digital handgrip
dynamometer

Digital handgrip
dynamometer

Digital handgrip
dynamometer

NA

NA

NA

NA

Cut-off score

Locally adapted

Locally validated

NR

NR

Tool validation

25.8 among
PLWH50+; and
25.3 among HIV
affected 50+ and
25.2 among the
uninfected older
adults ≥50 years.

Mean grip strength
in PLWH50+
(33.5 kg) was
weaker than
HIV-uninfected
individuals (38.3
kg).

25.7 among
PLWH50+; and
22.1 among the
uninfected older
adults ≥50 years.

Mean grip strength
change: 18.7 kgs
at bassline, 20.4
kgs at 12 weeks
and 23.1 kg at 2–3
years.

Prevalence
estimates/
other results for
PLWH50+

Women scored
poorly than
men. Married
respondents
had significantly
better scores
than widowed
and divorced
respondents.
Respondents with
at least secondary
education had
significantly better
scores.

When controlling
for age and sex
among those
aged 50 years and
older, HIV status
was significantly
associated with
weaker grip
strength.

NR

Reported
correlates not
aggregated by
age.

Correlates
reported

ART, antiretroviral treatment; B-FIT 2, Brief Frailty Instrument of Tanzania; NA, not applicable; NR, not reported; PLWH50+, people living with HIV ≥50 years old; PR, prevalence ratio.

51.0% on ART

NR

198 PLWH50+;
51.0% on ART
311 HIV uninfected
adults ≥50 years

Cross-sectional

Mugisha, (2013);
Uganda63

Digital handgrip
dynamometer

Treatment status Assessment tool
of PLWH
used

PLWH50+: 148 at ART naïve at
baseline; 72 at 12 baseline
wks, and 50 at 2–3
years ART

Randomised trial

Sample size

Filteau, (2017);
Zambia and
Tanzania18

Study design

Continued

Author,
publication year
and country

Table 2
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Sample size

400 PLWH50+;
About 22% on
732 HIV uninfected ART
older adults ≥50
years

Nyirenda, (2013);
Cross-sectional
Uganda and South
Africa70

28 PLWH50+;
NR
884 HIV uninfected
older adults ≥60
years

Cross-sectional

Cross-sectional

Yaya, (2019);
Togo52

Maniragaba,
(2018); Uganda66

90.5% on ART

154 PLWH50+;
726 PLWH (15–49
years)

Cross-sectional

Nyirenda, (2012);
South Africa65
203 PLWH50+;
23.7% on ART
219 HIV uninfected
older adults ≥50
years

198 PLWH50+;
51.0% on ART
311 HIV uninfected
older adults ≥50
years

Cross-sectional

Mugisha, (2013);
Uganda63

62 PLWH60+;
All on ART
124 HIV uninfected
older adults ≥60
years

Cross-sectional

Obimakinde,
(2020); Nigeria39

An adapted
version of the
WHOQOL-OLD

31-Item
WHOQOL-HIV
BREF

8-Item WHOQoL

8-Item WHOQoL

8-Item WHOQoL

8-item WHOQoL

Studies that utilised different versions of the WHO Quality-of-Life Scale (WHOQOL)

Study design

Treatment status Assessment tool
of PLWH
used

Summary of results for health-related quality of life

Author,
publication year
and country

Table 3

An index (good,
fair and poor
quality of life)
.

≥77.3 was
considered good
quality of life.

NA

NA

NA

NA

Cut-off score

NR

NR

Locally adapted

Locally adapted
and validated

NR

NR

Information
on local tool
validation
NR

Correlates
reported

Being female
and having been
previously married
was associated
with lower odds
of good QoL in
PLWH50+

PLWH had poor
quality of life
(OR 0.45; 95%
CI 0.22 to 0.93)
compared with
those who were
HIV uninfected.

Continued

Not aggregated by
HIV status

72.7% of
Correlates not
PLWH50 + had a aggregated by age
good global quality
of life compared
with 77.3% in the
younger PLWH.

Mean QoL
scores: 62.5
among PLWH50+;
and 59.4 in the
uninfected older
adults ≥50 years.

Older people
NR
in South Africa
were more likely
to have a better
quality of life (aOR
2.15, 95% CI 1.60
to 2.90) than in
Uganda.

Mean QoL
NR
scores: 57.2
among PLWH50+;
and 45.3 in the
uninfected older
adults ≥50 years

Mean QoL (SD):
82.7 (8.9) among
PLWH50+;
86.2 (6.5) in the
uninfected adults
≥50 years.

Prevalence
estimates/other
results
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Sample size

Cross-sectional

ART naïve

1337 adults aged 49.9% on ART
18–70 years (no of
PLWH50 + NR)

82 PLWH50+;
824 PLWH (18–49
years)

Cut-off score

Medical Outcome NA
Scale -HIV (MOS-
HIV)

HIV/AIDS-Targeted NA
Quality of Life
Scale

Treatment status Assessment tool
of PLWH
used

Previously
validated in other
SSA setting

Previously
validated in other
SSA settings

Information
on local tool
validation

Mean Mental
Health score: 46.4
among PLWH50+;
46.2 in PLWH
(18–49 years)
Physical health
score:
42.9 among
PLWH50+; and
44.8 in PLWH
(18–49 years)

Mean QoL
score: 68 among
PLWH50+, and
72.4 among PLWH
(18–49 years)

Prevalence
estimates/other
results

Reported
correlates not
aggregated by
age.

Reported
correlates not
aggregated by
age.

Correlates
reported

AOR, adjusted OR; ART, antiretroviral treatment; NA, not applicable; NR, not reported; PLWH50+, people living with HIV ≥50 years old; QoL, quality of life; SSA, sub-Saharan Africa.

Harding, (2014);
Kenya and
Uganda26

Parcesepe, (2020); Cross-sectional
Tanzania41

Studies that used other measures of quality of life

Study design

Continued

Author,
publication year
and country

Table 3
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DISCUSSION
Summary of main findings
Our review shows that the research on depression, anxiety,
cognitive function, frailty and HRQoL among PLWH50 +
in SSA is still scanty and largely concentrated in Uganda,
South Africa and Ethiopia. Overall, PLWH50 + presented
with wide-ranging prevalence of depression (6% to 59%),
cognitive impairment (4% to 61%) and frailty (3%–15%).
Additionally, the correlates of these outcomes were rarely
investigated. Nonetheless, those reported were mainly
sociodemographic variables, many of which were inconsistent. We find the current evidence inadequate to
characterise the real burden and determinants of these
outcomes in the region, partly because of the limited
number of well-
designed studies, heterogeneous findings, and substantial methodological limitations observed
in many included studies. Therefore, any policies and
programmes about the well-being of PLWH50 + in the
region have been made on the basis of minimal evidence.
The rising numbers of PLWH50 + in SSA and the potentially elevated burden of age-associated comorbidities in
this population warrant more research across the region.
Such data will provide the evidence needed to develop
appropriate policies, programmes and interventions for
the successful ageing of PLWH in SSA.
Depression and anxiety
Depression was the most frequently reported outcome in
about half of the included studies. This finding is consistent with the available literature on HIV, which recognises
depression as the most commonly occurring psychiatric
complication in this population.67 However, only two
studies investigated anxiety, a CMD with a similar prevalence to those seen in depression.68 The under investigation of anxiety disorders is of particular concern because
accumulating research involving PLWH50 + in HICs has
documented elevated anxiety levels, as high as 65%.68
More research is needed on this outcome in the region.
Our review also noted wide-
ranging prevalences
of depression and anxiety. This finding corroborates
previous review findings on the prevalence of CMDs in
the region, although in younger HIV populations.69 The
observed variation could reflect significant contextual
differences across the SSA region, for example, social
environmental milieu, healthcare systems, patterns of the
burden of diseases and mental health resources, which
are likely to alter the risk profile of these adults.70 It could
also be attributed to potential differences in study populations, study participants and the use of diverse measurement tools (including different cut-
offs for the same
measures). Indeed, in the current review, depression was
assessed using at least 10 different scoring systems with
diverse cut-off points. Besides, the majority of the studies
did not provide information on the reliability and validity
of the tools they used. Hence, it is difficult to draw firm
conclusions regarding the reliability, validity and applicability of many of the measures used to report this
outcome. The PHQ-9, for instance, was frequently used to
14

report depressive symptoms among the included studies.
However, most of the studies relied on previous validation
of the tool, the context of which was not given. A recent
review examining the validation of brief CMDs screening
tools in low-income and middle-income countries did not
support the use of PHQ-9 in these settings. It performed
poorly in several clinic populations with lower average
education but performed very well in high literate populations.71 This is especially an important consideration
in SSA, where older adults are more likely to have low
literacy levels. There is a need for rigorous cultural adaptation of these instruments to generate accurate epidemiological data that will inform proper intervention work
among PLWH50 + in SSA.
Hiv-associated cognitive impairment
The neurological involvement in HIV disease progression remains problematic, even in well-controlled PLWH,
resulting in poor quality of life. HIV associated cognitive
impairment is deemed one of the most prevalent comorbidities in the era of ART. Ageing with HIV would appear
to impose a synergistic impact, whereby increased comorbidities, such as hypertension, diabetes or depression,
likely contribute to and maintain HIV-associated cognitive impairment. In HICs, PLWH50 + have consistently
been shown to have high levels of cognitive impairments,
as high as 50%. The present review found a wide-ranging
associated cognitive impairment
prevalence of HIV-
(4%–61%). Our observation is consistent with the available literature, where the prevalence has been noted
to vary widely depending on sources used and appears
dependent on the populations studied, and approaches
used.72
Brief cognitive screening tools such as the Mini Mental
State Examination and International HIV Dementia Scale
(IHDS) were frequently used to document the prevalence of cognitive impairment compared with comprehensive neuropsychological batteries. While the use of
the brief screeners in low-resource settings is well understood given the resource gap, researchers should exercise
caution on the tools they use. Recent reviews evaluating
brief screening tools for neurocognitive impairment in
HIV/AIDS have indicated that some of the commonly
used tools, for example, the IHDS perform poorly, especially in screening milder cognitive impairments.73 74
In the current review, information on tool reliability or
validity was rarely reported. One of the studies reported
a limited diagnostic accuracy of the IHDS. However, the
OCS-Plus, one of the most recent screening tools, is promising. So far, the tool has only been used in South Africa
among older adults living with HIV, and its initial evaluation yielded excellent construct and external validity.75
This tool has the potential to address some of the unique
challenges and gaps facing resource-limited settings in
screening for HAND, including difficulty in performing
long test batteries, limited screening tools and a shortage
of clinical staff.
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810
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Frailty
Only two studies quantified the prevalence of frailty
among PLWH50+, ranging from 3% to 15%. One of the
studies was exclusively conducted among PLWH50+,
yielding a low frequency of frailty (3%). In the other study,
conducted in rural South Africa, the prevalence of frailty
was similar between PLWH50 + and their uninfected
counterparts (15% vs 18%, respectively). This finding
supports the growing evidence in SSA, which suggest
that older on effective ART have similar or better health
profiles than their uninfected counterparts, contrary to
what has been observed in HICs. At the global stage, the
frailty prevalence in SSA appears relatively lower than that
of HICs which ranges from 5% to 29%.76 The population
reaching older age in many SSA settings may be relatively
fit/active, still working, which may be true of PLWH,
potentially favouring better physical health in these individuals. Nonetheless, given the limited number of studies
on this outcome in SSA, these findings remain preliminary and inconclusive and highlight the urgent need for
more studies to shed more light on these observations.
Health-related quality of life
For some time, HRQoL has emerged as a salient indicator of HIV care and an essential target for HIV-related
research, aiming to expand the service paradigm
continuum.77 This new quality of life frontier has been
proposed as the ‘fourth 90’ to the original ‘90-90-90’
testing and treatment target championed by UNAIDS:
to ensure that 90% of people with viral load suppression
have good HRQoL.77 In the current review, research
on HRQoL among PLWH50 + was scanty. Thus, little
is known on the risk and protective factors of patient-
reported HRQoL. Further studies should explore the
independent effects of aging-
related conditions such
as CMDs, cognitive impairments and frailty on HRQoL
among PLWH50 + in SSA to support healthy ageing even
in the context of a chronic illness such as HIV infection.
Despite the observed limitations, the evidence of
better mental health,28 44 50 51 54 58 59 as well as cognition,53 61 frailty/handgrip strength47 62 63 and quality of
life,65 among PLWH50 + on ART (mainly among the
robust studies with low risk of bias) compared with uninfected older adults in the current review was striking.
This observation could be part of an emerging body of
evidence from SSA showing that the mental and well-
being outcomes among PLWH are comparable to those
without HIV. The mechanisms responsible for this observation are not well established and require further examination across many settings in SSA. However, it could be
attributed to a few plausible reasons, including (1) the
direct impact of ART on viral replication, inflammatory
pathways and downstream disease pathophysiology, the
so-
called ‘ART advantage’,78 79 (2) a survivorship bias
among PLWH50 + who access and remain in HIV care
and (3) beneficial spillover effects of ART programmes
such as enhanced access to and utilisation of primary care
services resulting in early identification and management
Mwangala PN, et al. BMJ Open 2021;11:e052810. doi:10.1136/bmjopen-2021-052810

of comorbid conditions.79–81 This observation could also
be related to the fact that PLWH50 + on ART are more
likely to use biomedical facilities due to better education
and higher socioeconomic status than their HIV uninfected peers. More studies, preferably longitudinal ones,
will shed more light on this observation. As it stands,
however, this finding offers an interesting contrast to the
commonly reported findings from HICs, which generally
show that PLWH50 + present with worse physical and
mental health outcomes compared with age-
matched
HIV uninfected people.5 68 82 These findings may suggest
context-
specific differences in the drivers of physical
and mental outcomes, including the demographic and
risk factor profile as well as the role of engagement in
HIV care—among those with and without HIV, especially when comparing low-income and middle-income to
HICs. Future studies should explore the extent to which
HIV programmes could be promoting the well-being of
PLWH50 + in SSA compared with HIV uninfected older
adults in the general population who are likely to bear the
brunt of the prevailing poor health systems and primary
care systems in the region.
The correlates of mental and well-being outcomes
The correlates of CMDs, cognitive impairment, frailty and
HRQoL have been scarcely investigated in SSA. In the
current review, the frequently reported correlates were
sociodemographic in nature, many of which (eg, age,
formal education levels and wealth status) were inconsistent. However, being female was consistently associated
with declining mental health, cognitive function, HRQoL
and frailty status. This finding mirrors the results of a
recent review of older women’s physical and psychological health residing in SSA, which indicated that women
were significantly more likely to report poor health
compared with men.83 This finding highlights the need
for adequate representation of both sexes in research
studies, incorporating a gender lens in their analyses to
understand better the unique health challenges that each
gender faces. Further studies are also urgently needed in
SSA to identify potential risk and protective factors, especially those that could be modified, to suggest how to best
integrate the management of these impairments in HIV
care guidelines in SSA. Future studies should explore the
influence of HIV-related factors, psychosocial risk (eg,
loneliness, ageism, stigma, social support, living arrangements) and other comorbidities on the health and well-
being of PLWH50+. To promote healthy ageing in the
context of chronic conditions, such as HIV infection, the
psychological and social domains are especially critical
as they could be a way to compensate for physiological
limitations (ie, multiple chronic conditions) and allow
even in the context of disease and disability, to experience optimal quality of life.
Strengths and limitations
To our knowledge, this is the first comprehensive review
of CMDs, cognitive impairment, frailty and HRQoL
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among PLWH50 + living in SSA. Our expanded search of
five online databases and snowballing techniques minimised the risk of missing relevant studies. However, our
review should be considered in the context of important
limitations. Despite a thorough search strategy, some
articles may have been missed, especially in excluding
non-English language studies. However, these were very
few. The substantial amount of heterogeneity across the
studies in terms of, for example, study design, operationalisation of age, definitions of outcomes and measures
made comparisons difficult and did not allow a meta-
analysis to be done. Furthermore, most of the studies
recruited PLWH50 + from HIV clinics whose attendees
may represent the less-
healthy end of the spectrum
of service users leading to overestimation of reported
outcomes. Conversely, those at the filter end of the cohort
may be more able to attend or be proactive concerning
their well-being, leading to underestimation of outcomes.
Besides, the substantial methodological limitations
observed might have biased the reported findings, hence
limiting their external validity.

CONCLUSIONS
Overall, the existing research on the burden and determinants of mental and well-
being outcomes among
PLWH50 + in SSA is scantly addressed. We also noted
substantial limitations in many of the included studies,
which need to be addressed in future studies. Our findings underscore the need to increase the evidence base
of these outcomes in the region. Future studies should:
(1) explicitly target older persons ≥50 years living with
HIV, (2) carefully select a comparison group and have
sufficient sample sizes for adequate statistical testing, (3)
expand the geographical distribution of these studies in
many SSA settings and use adequately standardised survey
tools adapted for the region and (4) generate more
data on the risk and determinants of these outcomes
using a gender lens. There is also an ongoing need for
designed longitudinal cohort studies to study the
well-
temporal patterns of these outcomes in the region.
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